arrow
G

G. Justeau

université de rennes
H指数:8
被引数:376

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Treatment patterns and outcomes in advanced and metastatic lung cancer in France: Results from the Epidemiological Strategy and medical Economics (ESME) database lung cancer in France

法国晚期和转移性肺癌的治疗模式与结果:来自法国流行病学策略与医学经济学(ESME)数据库的研究结果

2026-08-010
PRE
Female pulmonologists experienced poorer health and reduced quality of life related to their professional activities

女性肺科医生因专业活动经历更差的健康状况和降低的生活质量

2026-04-130
PRE
Association of sleep-related hypoxemia with survival in patients with non-small cell lung cancer – the NEOSAS-GFPC study group

睡眠相关低氧血症与无小细胞肺癌患者生存率的相关性——NEOSAS-GFPC研究小组

CHEST
IF8.6
2026-03-090
PRE
First-Line Pembrolizumab Efficacy in Octogenarians With NSCLCs Expressing ≥ 50% PD-L1 (ESCKEYP GFPC 05-2018)

一线帕博利珠单抗在PD-L1表达≥50%的80岁及以上非小细胞肺癌患者中的疗效(ESCKEYP GFPC 05-2018)

2025-03-040
PRE
Real-world treatment and retreatment patterns and outcomes in patients with advanced or metastatic non-small cell lung cancer following nivolumab monotherapy in second line or later in France: an I-O Optimise analysis
2025-02-200
OAAI
French pulmonologists suffered from impaired health and quality of life due to their work
2024-10-300
PRE
Association of sleep-related hypoxia with survival in patients with non-small cell lung cancer - the NEOSAS-GFPC study group
2024-10-300
PRE
A national real-world analysis of ROS1+metastatic non-small cell lung cancer patients management (explore ALK, cohort 2, GFPC 03-2019)

一项关于ROS1+转移性非小细胞肺癌患者管理的全国性真实世界分析(探索ALK,队列2,GFPC 03-2019)

2024-09-010
PRE
Explore-ALK (GFPC 03-2019): A real-world prospective, multicenter study of advanced ALK rearranged non-small cell lung cancer patients

探索-ALK (GFPC 03-2019):一项真实世界前瞻性、多中心研究,探讨ALK重排的非小细胞肺癌患者

2024-09-010
PRE
Real-world overview of therapeutic strategies and prognosis of older patients with advanced or metastatic non-small cell lung cancer from the ESME database
2024-09-010
PRE
Predictors of three-month mortality and severe chemotherapy-related adverse events in patients aged 70 years and older with metastatic non-small-cell lung cancer: A secondary analysis of ESOGIA-GFPC-GECP 08-02 study
2024-07-015
OA
Three-Year Overall Survival of Patients With Advanced Non-Small-Cell Lung Cancers With ≥50% PD-L1 Expression Treated With First-Line Pembrolizumab Monotherapy in a Real-World Setting (ESCKEYP GFPC Study)
2023-10-090
PRE
Complex urban atmosphere alters alveolar stem cells niche properties and drives lung fibrosis
2023-10-012
PRE